Welcome to LookChem.com Sign In|Join Free

CAS

  • or

5215-92-9

Post Buying Request

5215-92-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

5215-92-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 5215-92-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,2,1 and 5 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 5215-92:
(6*5)+(5*2)+(4*1)+(3*5)+(2*9)+(1*2)=79
79 % 10 = 9
So 5215-92-9 is a valid CAS Registry Number.

5215-92-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-methyl-4-nitropentan-1-ol

1.2 Other means of identification

Product number -
Other names 4-methyl-4-nitro-pentan-1-ol

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:5215-92-9 SDS

5215-92-9Relevant articles and documents

-

Feuer,Kucera

, p. 5740 (1955)

-

MULTIVALENT RAS BINDING COMPOUNDS

-

Paragraph 00880, (2017/07/23)

Described herein are compounds that modulate Ras signaling, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with altered Ras signaling. Further described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds and methods of using such compounds in the treatment of cell proliferative disorders, including cancer.

Novel Enantiomeric Pure Beta Agonists, Manufacturing and Use as a Medicament Thereof

-

Page/Page column 8, (2008/06/13)

The present invention relates to enantiomerically pure compounds of formula 1 wherein the groups m, n, B, X, R1, m and Ym- may have the meanings given in the claims and specification, methods for preparing them and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 5215-92-9